Owing to this expertise, we have identified a novel SARS-CoV-2 entry inhibitor with a broad spectrum of activity against human coronaviruses and an acceptable toxicity profile:

• Jiao F, Andrianov AM, Wang L, Furs KV, Gonchar AV, Wang Q, Xu W, Lu L, Xia S, Tuzikov AV, Jiang S. Repurposing Navitoclax to block SARS-CoV-2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein. J Med Virol. 2023 Oct;95(10):e29145. doi: 10.1002/jmv.29145. PMID: 37804480.

We have also identified new molecules with high efficacy against tuberculosis:

• Andrianov AM, Furs KV, Gonchar AV, Skrahina AM, Wang Y, Lyu LD, Tuzikov AV. Virtual screening and identification of promising therapeutic compounds against drug-resistant Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein synthase I (KasA). J Biomol Struct Dyn. 2025 Mar;43(4):2029-2041. doi: 10.1080/07391102.2023.2293276. Epub 2023 Dec 13. PMID: 38088766.

We are also exploring the application of AI in drug discovery, particularly its potential for the de novo generation of chemical compounds:

• Andrianov AM, Shuldau MA, Furs KV, Yushkevich AM, Tuzikov AV. AI-Driven De Novo Design and Molecular Modeling for Discovery of Small-Molecule Compounds as Potential Drug Candidates Targeting SARS-CoV-2 Main Protease. Int J Mol Sci. 2023 Apr 29;24(9):8083. doi: 10.3390/ijms24098083. PMID: 37175788; PMCID: PMC10178971.

A full list of our publications is available on our Research Gate page .